Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and their care partners. The objective of this qualitative study phase was to identify a comprehensive set of concepts of interest that are meaningful to individuals across the AD continuum. Methods: Interviews were conducted with 60 clinically referred individuals and care partners across 5 AD stages (n = 12 each): group 1 (non-clinically impaired individuals with AD pathology), group 2 (individuals with mild cognitive impairment and AD pathology), group 3 (individuals with mild AD), group 4 (individuals with moderate AD and their care partners), and group 5 (care partners of individuals with severe AD). Interviews were conducted by experienced interviewers, audio-recorded, and transcribed. Dominant trends were identified in each interview and compared across subsequent interviews to generate themes or patterns in descriptions of AD symptoms, impacts, and desired treatment outcomes. Results: All participants endorsed current issues related to memory; nearly all participants (n = 55; 92%) across the five groups endorsed symptoms related to communication and language. Groups 1–3 reported an impact on mood/emotions (n = 23; 64%) and a decrease in social activities or outgoingness (n = 17; 47%). Current and future concerns reported by the overall sample included memory (n = 48; 80%), dependence (n = 40; 67%), and “other” concerns (n = 33; 55.0%) (e.g., uncertainty about the future, burdening others). The most desired AD treatment outcomes were improvement or restoration of memory (n = 40; 67%) and stopping AD progression (n = 35; 58.3%). Group-level differences were observed in the symptoms, impacts, and desired treatment outcomes among patients and care partners across the AD continuum. Conclusions: Cognitive functioning issues—particularly in memory and communication—are present even in preclinical and early-stage AD, including among those without a formal AD diagnosis. While the impacts of AD vary across the disease-severity spectrum, improved memory and disease modification were treatment outcomes considered most important to participants across all 5 AD stages. Neuropsychological assessments traditionally used in AD clinical trials may not evaluate the often-subtle concepts that are important to patients and care partners. Results from this study will inform the second phase of the WMM project—a quantitative study to elicit the relative importance of these concepts of interest to people at risk for and living with AD and their care partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vasileiou, K., Barnett, J., Thorpe, S., & Young, T. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0594-7 · Cited by 3,115
Cited by
Lecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191
Expectations and clinical meaningfulness of randomized controlled trials
Petersen, R. C., Aisen, P. S., Andrews, J. S., Atri, A., Matthews, B. R., Rentz, D. M., Siemers, E. R., Weber, C. J., & Carrillo, M. C. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12959 · Cited by 95
“13,23 For example, in the memory domain, a CDR of 0.5 is described as “mild consistent forgetfulness; partial recollection of events; ‘benign’ forgetfulness.””
BackgroundInfluentialLott, S. A., Streel, E., Bachman, S. L., Bode, K., Dyer, J., Fitzer-Attas, C., Goldsack, J. C., Hake, A., Jannati, A., Fuertes, R. S., et al. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.103 · Cited by 48
Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
Metadata
- Authors
- DiBenedetti, D. B., Slota, C., Wronski, S. L., Vradenburg, G., Comer, M., Callahan, L. F., Winfield, J., Rubino, I., Krasa, H. B., Hartry, A., Wieberg, D., Kremer, I. N., Lappin, D., Martin, A. D., Frangiosa, T., Biggar, V., & Hauber, B.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2020-07-30
- Volume
- 12
- Issue
- 1
- Pages
- 90-90
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W3045853079
- Cited by
- 80
- References
- 1
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. https://app.cochat.ai/papers/10.1186/s13195-020-00659-6
- The paper
- DiBenedetti, D. B., Slota, C., Wronski, S. L., Vradenburg, G., Comer, M., Callahan, L. F., Winfield, J., Rubino, I., Krasa, H. B., Hartry, A., Wieberg, D., Kremer, I. N., Lappin, D., Martin, A. D., Frangiosa, T., Biggar, V., & Hauber, B. (2020). Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00659-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.